In a research article published today in BMJ Open, former Lab Fellow Jennifer E. Miller, Faculty Associate David Korn, and Joseph S. Ross examine clinical trial results disclosure by large pharmaceutical companies and conclude that it falls below legal and ethical standards. The article also introduces an annual transparency scorecard which audits and ranks all new medicines and vaccines.
According to today's press release, "a critical issue facing the biopharmaceutical industry today is the loss of public trust,” said Jennifer E. Miller, Ph.D., president of Bioethics International, assistant professor of medical ethics in the Department of Population Health at NYU Langone Medical Center and lead author on the paper. “Only 17 years ago, the pharmaceutical industry was among the most admired business sector in the world, and today only 12 percent of Americans believe that pharmaceutical companies are honest and ethical. The Good Pharma Scorecard enables the biopharmaceutical industry to evaluate its performance across key areas of ethical and legal concern and offers companies the ability to publicly demonstrate meaningful improvement in trustworthiness over time.”
Read more here.